Vistogard is a brand name for the medication ticagrelor [1]. Ticagrelor is an antiplatelet medication used to prevent blood clots in patients with acute coronary syndrome (ACS) [2][3]. It works by inhibiting adenosine diphosphate (ADP) from binding to its P2Y12 receptor on platelets, thereby reducing platelet activation and aggregation [4].
What is ticagrelor prescribed for?
Ticagrelor is prescribed to reduce the risk of thrombotic events, such as heart attack and stroke, in patients with a history of acute coronary syndrome [2][3]. It is typically used in combination with aspirin [5].
How does ticagrelor work?
Ticagrelor is a direct-acting, reversibly binding P2Y12 receptor antagonist [4]. By blocking the P2Y12 receptor on platelets, it prevents adenosine diphosphate (ADP) from triggering platelet aggregation [4]. This action helps to reduce the formation of blood clots that can lead to heart attacks and strokes [2][3].
What is the difference between ticagrelor and clopidogrel?
Ticagrelor and clopidogrel are both P2Y12 inhibitors used for similar indications, but they have key differences. Ticagrelor is a direct-acting, reversible inhibitor, meaning it binds and unbinds to the P2Y12 receptor quickly [4]. Clopidogrel, on the other hand, is a prodrug that requires metabolic activation and has an irreversible binding mechanism [4][6]. Clinical trials have shown ticagrelor to be more effective than clopidogrel in reducing ischemic events, although it may also be associated with a higher rate of bleeding [7].
What are the common side effects of ticagrelor?
Common side effects of ticagrelor can include dyspnea (shortness of breath), bleeding, and bruising [2][8]. More serious side effects can include severe bleeding events and bradycardia (slow heart rate) [2].
How long does it take for ticagrelor to start working?
Ticagrelor begins to inhibit platelet aggregation within a short period after administration, with peak effect usually achieved within 1 to 3 hours [4].
Can ticagrelor be taken with other medications?
Ticagrelor is often prescribed with aspirin [5]. However, caution is advised when co-administering ticagrelor with other medications that increase bleeding risk, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or warfarin [2]. It is also important to inform healthcare providers about all other medications being taken, including over-the-counter drugs and herbal supplements [2][8].
What are the risks of stopping ticagrelor early?
Stopping ticagrelor prematurely, especially in patients who have had a recent stent placement or ACS event, can increase the risk of thrombotic events, including stent thrombosis, myocardial infarction (heart attack), and death [9]. It is crucial to discuss any intention to stop ticagrelor with a healthcare professional [9].
When does the patent for ticagrelor expire?
Information regarding specific patent expiry dates for Vistogard (ticagrelor) is not readily available in the provided context. However, patent protection for drugs typically lasts for a set period, after which generic versions may become available.
Who manufactures Vistogard?
Vistogard is the brand name for ticagrelor manufactured by AstraZeneca [1].
What are the clinical trial results for ticagrelor?
Key clinical trials, such as the PLATO trial, demonstrated that ticagrelor, in combination with aspirin, was more effective than clopidogrel plus aspirin in reducing the composite endpoint of cardiovascular death, myocardial infarction, and stroke in patients with ACS [7]. However, the PLATO trial also noted a numerically higher rate of overall bleeding with ticagrelor compared to clopidogrel [7].
What is the generic name for Vistogard?
The generic name for Vistogard is ticagrelor [1].
---
Sources
[1] https://www.ncbi.nlm.nih.gov/drug_chemical/441840
[2] https://medlineplus.gov/druginfo/meds/a611009.html
[3] https://www.uptodate.com/contents/ticagrelor-drug-information
[4] https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.111.027969
[5] https://www.heart.org/en/health-topics/heart-attack/treatment-after-a-heart-attack/heart-attack-medications
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128553/
[7] https://www.nejm.org/doi/full/10.1056/NEJMoa0904327
[8] https://www.webmd.com/drugs/2/drug-150036/vistogard-oral-tablet/details
[9] https://www.pharmacyservices.nhs.uk/medicine-information/medicines-guidance/ticagrelor-drug-guidance/